NYSE:QGENLife Sciences
Evaluating Qiagen (NYSE:QGEN) After New Bundibugyo Ebolavirus Digital PCR Assays Catch Investor Attention
Why Qiagen’s new Bundibugyo ebolavirus assays caught the market’s attention
Qiagen (QGEN) recently announced research use digital PCR assays for Bundibugyo ebolavirus, and the stock rose 3.0% on June 4, 2026, as investors weighed this product launch.
The new assays are designed for the QIAcuity digital PCR system and target nucleoprotein and VP35 regions using publicly available outbreak genomic data. This development reinforces Qiagen’s role in infectious disease research workflows.
See our...